Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marinus Pharma CS
(NQ:
MRNS
)
1.420
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharma CS
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
June 08, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 03, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
May 18, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
74 Biggest Movers From Yesterday
June 03, 2022
Gainers
Via
Benzinga
Recap: Marinus Pharma Q1 Earnings
May 12, 2022
Marinus Pharma (NASDAQ:MRNS) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Marinus Pharma beat estimated...
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 12, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 10, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 05, 2022
Via
Benzinga
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
May 05, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
3 Biotech Stocks Under $10 to Add to Your Buy List
April 26, 2022
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk.
Via
InvestorPlace
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
April 20, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
April 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
March 31, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Analyzing Marinus Pharmaceuticals Inc's Short Interest
March 22, 2022
Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) short percent of float has risen 9.74% since its last report. The company recently reported that it has 1.23 million shares sold short...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 21, 2022
Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.
Via
Benzinga
Recap: Marinus Pharmaceuticals Q4 Earnings
March 21, 2022
Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q4 earnings results on Monday, March 21, 2022 at 07:15 AM. Here's what investors need to know about the announcement...
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 21, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Earnings Scheduled For March 21, 2022
March 21, 2022
Companies Reporting Before The Bell • Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at $0.76 per share on revenue of $3.37 million. •...
Via
Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
March 20, 2022
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment...
Via
Benzinga
Here's Why Marinus Pharmaceuticals Shares Are Moving
March 18, 2022
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares are trading higher by 25.0% at $10.72 after the company announced the FDA has approved ZTALMY oral suspension for the...
Via
Benzinga
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
March 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Preview: Marinus Pharmaceuticals's Earnings
March 18, 2022
Marinus Pharmaceuticals (NASDAQ:MRNS) is set to give its latest quarterly earnings report on Monday, 2022-03-21. Here's what investors need to know before the announcement....
Via
Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
March 15, 2022
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
March 02, 2022
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
March 02, 2022
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 25, 2022
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.